Clinical efficacy of combination therapy with iron and folic acid in reproductive-age patients with abnormal uterine bleeding

Introduction. The high prevalence of iron deficiency in women with abnormal uterine bleeding (AUB) requires optimizing therapeutic approaches. Aim: to evaluate the clinical efficacy and safety of therapy with iron fumarate in combination with folic acid in reproductiveage patients with AUB complicated by iron deficiency anemia (IDA) and latent iron deficiency (LID). Materials and М ethods. There were retrospectively analyzed 75 outpatient patient records (2021–2025) stratified as follows: 40 patients with IDA (hemoglobin level < 120 g/L) and 35 patients with LID (ferritin content < 30 ng/ml). Patients received iron fumarate 163.56 mg (equivalent to 50 mg iron) + folic acid 540 μg (equivalent to 500 μg dry matter) for a course of 12 weeks. Treatment efficacy was assessed according to the hemoglobin, ferritin and sideropenic syndrome severity scales. Results. A statistically significant increase in red blood parameters in all groups (p < 0.001) was recorded during treatment. The following changes were found: in IDA group median hemoglobin and ferritin level increased from 110 to 123 g/L and from 12 to 21 ng/ml, respectively; in LID group – from 123 to 136 g/L and from 22 to 34 ng/ml, respectively. Conclusion. Combination therapy with iron and folic acid preparations demonstrates high efficacy and safety in correcting anemic and sideropenic syndromes in patients with AUB, which justifies the expediency of its inclusion in the management standards for this category of patients.